Talaris Therapeutics reported the appointment of Sapna Srivastava, Ph.D., and Gaurav Shah, M.D., as independent representatives to its Board of Directors. Dr. Srivastava, who will also become the Chairperson of Talaris' Audit Committee, has almost 20 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street. Most recently, she was the Chief Financial and Strategy Officer for Abide Therapeutics (acquired by Lundbeck). Prior to Abide, she was the Chief Financial and Strategy Officer for Intellia Therapeutics, where she played a key role in leading the company's financial operations, private and public equity financings, strategic alliances and direction. Dr. Shah is the founding Chief Executive Officer and President of Rocket Pharma, with a pipeline comprised of first-in-class gene therapies for rare and devasting inherited genetic diseases. Prior to this role, Dr. Shah was Global Program Head in the Cell & Gene Therapies Unit at Novartis, where he had strategic oversight of 12 functions and helped spearhead pivotal trials with CART-19 for patients with leukemia and lymphoma.